一个接受丁素硫酸盐的儿童的焦点发作:一个案例报告
Falah Nadeem1, Maria Ali2, Nida Hameed3
1Pediatrics, Rashid Latif Medical College, Lahore, PAK.
Cureus
|September 18, 2023
概括
一种支气管扩展剂的硫酸特尔布他林可以在婴儿中引起焦点发作. 这份病例报告强调了在患有新发作的儿科患者中考虑这种罕见的不良影响的重要性.
科学领域:
- 儿科神经学 儿科神经学
- 药理学 药理学是指药理学的学科.
- 临床病例报告 临床病例报告
背景情况:
- 特尔布他林硫酸盐是一种选择性β-2上腺素受体激动剂,用于喘的支气管扩展剂.
- 常见的副作用包括,低心率和头.
- 发作不是经常报告的甲酸的副作用.
研究的目的:
- 报告婴儿中焦点发作病例,可能与硫酸丁有关.
- 提高儿童群体对罕见药物不良反应的认识.
主要方法:
- 一个5个月大的女孩出现焦点发作的案例研究.
- 通过临床病史,脑电图 (EEG) 和电解质面板排除其他潜在的病因.
- 在停止使用硫酸丁时,发作停止的观察.
主要成果:
- 婴儿经历了焦点发作后的丁胺硫酸盐糖的管理.
- 在停止服用药物后,没有观察到发作的复发.
- 排除了婴儿发作的其他常见原因.
结论:
- 焦点发作可能是丁氨酸硫酸在婴儿中的罕见不良反应.
- 临床医生应保持高的药物诱导的怀疑指数,在儿童患者新发的焦点.
相关概念视频
Seizures: Classification
406
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
406
Antiepileptic Drugs: Sodium Channel Blockers
652
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
652
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
339
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
339
Antiepileptic Drugs: GABAergic Pathway Potentiators
452
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
452
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


